ARTICLE | Regulation
For want of a nail
Delays for Horizant RLS drug provide lessons on bringing repurposed drugs to FDA
May 23, 2011 7:00 AM UTC
See Sidebar: Horizons beyond Horizant
FDA's handling of an NDA for Horizant gabapentin enacarbil looked like exactly the kind of thing that provides grist to critics who say the agency is needlessly delaying access to effective new medicines...